$95.00Original price was: $95.00.$52.00Current price is: $52.00.
AOD9604 is a modified version of the hGH fragment 176-191 peptide (contains a di-sulfide bridge) and thus a derivative of human growth hormone (hGH). Originally developed as a lipolytic (fat burning) compound, AOD9604 has shown benefit in studies of heart disease, osteoarthritis/cartilage repair, and metabolic syndrome. AOD9604 stimulates lipolysis (the breakdown or destruction of fat) and inhibits lipogenesis in animal studies.
AOD-9604 is administered once daily via subcutaneous injection, typically in the lower abdominal or thigh area. A starting dose of 300 mcg (0.3 ml) is commonly recommended for those beginning treatment. Based on individual response and metabolic goals, the dose may be increased to 500 mcg (0.5 ml) and, if well tolerated, up to 1 mg (1 ml) per day.
A typical escalation schedule is as follows:
Week 1–2: 300 mcg (0.3 ml) daily
Week 3–4: 500 mcg (0.5 ml) daily
Week 5 and beyond: 500–1000 mcg (0.5–1 ml) per day, 5 to 7 days per week
For fat loss protocols, cycles typically last 6 to 12 weeks, followed by a rest or maintenance phase. AOD-9604 is most effective when combined with diet and exercise. Injections are best taken on an empty stomach in the morning or pre-exercise.
AOD-9604 is a synthetic peptide fragment derived from the C-terminal region (amino acids 176–191) of human growth hormone (hGH). Unlike full-length GH, AOD-9604 is non-hormonal, with no effect on IGF-1 or systemic growth hormone levels.
It was originally developed to target fat metabolism by promoting lipolysis and preventing lipogenesis. AOD-9604 supports body fat reduction, especially visceral fat, and may improve metabolic efficiency, making it ideal for weight management programs.
Because it does not influence glucose, insulin, or IGF-1 levels, AOD-9604 is considered safer than traditional GH therapy and can be used long-term with minimal risk.
AOD-9604 exerts its effect by mimicking the fat-burning region of hGH, without affecting the rest of the hormone’s activity. It acts through beta-3 adrenergic receptors, promoting fat breakdown and blocking fat storage.
Mechanisms include:
Stimulating lipolysis (breakdown of stored fat)
Inhibiting lipogenesis (formation of new fat cells)
Activating fat-burning enzymes in adipose tissue
Enhancing mitochondrial oxidation of fatty acids
Unlike hGH, it does not impact muscle growth, blood glucose, or bone density, making it highly specific for fat metabolism.
Due to the lack of human data, AOD-9604 should not be used during pregnancy or breastfeeding. Although non-hormonal, its impact on fetal development or milk production is not well studied.
AOD-9604 is not FDA-approved for pediatric use. While some studies have investigated its role in pediatric obesity, it should only be used under medical supervision and within clinical trials for children.
AOD-9604 is not FDA-approved for therapeutic use in the United States. However, it has GRAS (Generally Recognized As Safe) status in select countries for oral supplement use. Injectable formulations are classified as investigational compounds and are available through compounding pharmacies for clinician-directed protocols.
